Research programme: halimide analogues - NereusAlternative Names: NPI 2350; NPI 2362; NPI 2386; NPI 2460
Latest Information Update: 16 Oct 2007
At a glance
- Originator Kyoto University; University of California System
- Developer Nereus Pharmaceuticals
- Class Small molecules
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer